Opdivo Multiple Myeloma Clinical Trials Halted Following Keytruda Deaths
Federal health officials have placed a hold on three clinical trials designed to test the combination of advanced lung cancer treatments with various other forms of cancer drugs for treatment of multiple myeloma, after reports of several patient deaths with a similar drug.
Bristol-Myers Squibb issued a press release on September 6, announcing that the FDA has halted the studyes that were testing Opdivo in conjunction with Celgene’s Revlimid or Pomalyst medications, which are the same medications used in conjunction with Keytruda multiple myeloma studies that resulted in several patient deaths. Opdivo and Keytruda are similar, competing cancer drugs known as immune checkpoint inhibitors.
Multiple myeloma is a form blood cancer related to lymphoma and leukemia, in which Merck’s Keytruda and Bristol-Myers Squibb’s Opdivo were being tested in separate clinical trials, pairing them with the chemotherapy drug dexamethasone and either Celgene’s Revlimid or Pomalyst, as a potential new form of treatment.
Did You Know?
Millions of Philips CPAP Machines Recalled
Philips DreamStation, CPAP and BiPAP machines sold in recent years may pose a risk of cancer, lung damage and other injuries.Learn More
Following patient deaths in two Keytruda clinical studies, the FDA halted any further advancement and new patient registration for both companies, out of an abundance of caution. The agency said the risks of severe adverse events, including death, appeared to outweigh any benefits of using the drug combinations to treat multiple myeloma. The Opdivo trials are being halted due to the close similarities between Keytruda and Opdivo.
The FDA is ordering patients currently taking part in the Opdivo trials to continue with the regimens, as long as they are experiencing clinical benefit. However, no new patients can enroll in the studies.
Opdivo studies affected by the FDA’s decision include CheckMate-602, CheckMate-039, and CA204142.
The FDA previously issued a safety alert for two Keytruda studies on August 31, 2017 after finding the medication used in combination with some other medications to treat multiple myeloma may be deadly for some patients.
The FDA warning came after data from the KEYNOTE-183 trial, which involved about 250 patients, indicated that patients given Keytruda had a 61% increased risk of death, with 29 deaths in the Keytruda arm of the clinical trial, compared to only 21 deaths among the control subjects.
Furthermore, the Keytruda KEYNOTE-185 clinical trial, involving about 300 patients, saw an even higher risk, with more than twice as many Keytruda patients dying than those in the control group, 19 to 9. That trial also showed that 54% of the patients given a Keytruda-based drug combination had a 54% chance of severe adverse health effects, compared to only 39% in the control group.
The FDA is asking healthcare professionals and patients who experience any adverse events or side effects during Keytruda treatment to report them to the FDA’s MedWatch Adverse Event Reporting Program.
SueMay 2, 2020 at 3:46 am
In 2012 my husband was diagnosed with Renal Cell Carsanoma for which there is no chemo treatment. In 2019 he was told by his Oncologist that he may want to consider immuno therapy and after one infusion of Opdivo the drug started to attack all his vital organs and ultimately caused his death in May 2019. We were not told at the time of treatment that this drug was so new that even the doctors did [Show More]In 2012 my husband was diagnosed with Renal Cell Carsanoma for which there is no chemo treatment. In 2019 he was told by his Oncologist that he may want to consider immuno therapy and after one infusion of Opdivo the drug started to attack all his vital organs and ultimately caused his death in May 2019. We were not told at the time of treatment that this drug was so new that even the doctors did not know how to reverse the horrific side effects. They were brutal!! I feel my husband would still be alive today if he had not taken Opdivo!!! His Oncologist agreed that his cancer was not what he died from it was that toxic drug.
SharonJanuary 30, 2020 at 8:57 pm
My husband was scheduled for 26 treatments after # 4 shut down his pituitary gland , almost killed him. Now has lifelong effects from this drug. Use extreme caution when advised to take this as a treatment.
DebraJuly 25, 2019 at 7:02 pm
On the fourth day after my husband's second Opdivo infusion, he was in the hospital with a glucose reading of 1,100. He is now a type 1 diabetic and has had severe diarrhea for over 5 months. Please do not take this drug. It has life altering consquences.
cvSeptember 26, 2017 at 6:37 pm
I am gut sick about this treatment. My husband had two chemo treatments and then was changed to Opdivo. It was not clinical trial. Why on earth would a pharm. company allow their drug to be given to someone without a spleen, since it works with your immune system. They did not think twice about helping with funding, do they educate the doctors. There is no doubt in my mind, my husband would s[Show More]I am gut sick about this treatment. My husband had two chemo treatments and then was changed to Opdivo. It was not clinical trial. Why on earth would a pharm. company allow their drug to be given to someone without a spleen, since it works with your immune system. They did not think twice about helping with funding, do they educate the doctors. There is no doubt in my mind, my husband would still be here if not for the side effects and lack of information given to us on this drug.
"*" indicates required fields
More Top Stories
A Bard Infuse-A-Port lawsuit claims a piece of a failed port catheter broke off, causing a woman to suffer a pulmonary embolism which has resulted in fragments of the device remaining in her heart.
A Wegovy gastroparesis lawsuit blames the weight loss drug for a stomach paralysis problems which left a woman with permanent injuries.
Uber faces a lawsuit from four passengers who say they were sexually assaulted by drivers, due to the company's lack of security measures and focus on passenger safety.